Market Research Logo

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016’, provides in depth analysis on Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted pipeline therapeutics.

The report provides comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
    • The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


    Introduction
    Global Markets Direct Report Coverage
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Overview
    Therapeutics Development
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Stage of Development
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Therapy Area
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Indication
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Products Glance
    Late Stage Products
    Early Stage Products
    Unknown Stage Products
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Companies
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Universities/Institutes
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
    Assessment by Monotherapy/Combination Products
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
    Aptose Biosciences Inc.
    Arvinas, Inc.
    C4 Therapeutics, Inc.
    Constellation Pharmaceuticals, Inc.
    ConverGene, LLC
    Daiichi Sankyo Company, Limited
    Dybly AG
    F. Hoffmann-La Roche Ltd.
    Incyte Corporation
    Kainos Medicine, Inc.
    Merck & Co., Inc.
    Resverlogix Corp.
    Trillium Therapeutics Inc.
    Zenith Epigenetics Corp
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
    apabetalone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-763 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-771 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-825 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    birabresib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CK-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPI-0610 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CVG-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DYB-186 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INCB-54329 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KM-601 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MA-2014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MS-417 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-2734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-51107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-6146 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-2535 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target BRD4 and VHL for Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target BRD4 and VHL for Ovarian Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRX-2523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-281 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZEN-3365 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZEN-3694 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Projects
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Featured News & Press Releases
    Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial
    Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
    Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
    Jun 02, 2016: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
    May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
    Jan 25, 2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
    Nov 11, 2015: Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
    Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
    Oct 26, 2015: Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
    Sep 29, 2015: Resverlogix Provides Research and Development Update in New York City
    Sep 24, 2015: Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
    Aug 31, 2015: Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
    Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 apabetalone
    Jun 22, 2015: Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
    Jun 08, 2015: Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Indication, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Number of Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Pipeline by Aptose Biosciences Inc., H2 2016
    Pipeline by Arvinas, Inc., H2 2016
    Pipeline by C4 Therapeutics, Inc., H2 2016
    Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
    Pipeline by ConverGene, LLC, H2 2016
    Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Pipeline by Dybly AG, H2 2016
    Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Pipeline by Incyte Corporation, H2 2016
    Pipeline by Kainos Medicine, Inc., H2 2016
    Pipeline by Merck & Co., Inc., H2 2016
    Pipeline by Resverlogix Corp., H2 2016
    Pipeline by Trillium Therapeutics Inc., H2 2016
    Pipeline by Zenith Epigenetics Corp, H2 2016
    Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Top 10 Indication, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report